Ethoxyquin Inhibits the Progression of Murine Ehrlich Ascites Carcinoma through the Inhibition of Autophagy and LDH
Journal article
Tayel, Fekria, Mahfouz, Magdy E., Salama, Afrah F. and Mansour, M. (2021). Ethoxyquin Inhibits the Progression of Murine Ehrlich Ascites Carcinoma through the Inhibition of Autophagy and LDH. Biomedicines. 9 (11), p. e1526. https://doi.org/10.3390/biomedicines9111526
| Authors | Tayel, Fekria, Mahfouz, Magdy E., Salama, Afrah F. and Mansour, M. |
|---|---|
| Abstract | Cancer cells exhibit an increased glycolysis rate for ATP generation (the Warburg effect) to sustain an increased proliferation rate. In tumor cells, the oxidation of pyruvate in the Krebs cycle is substituted by lactate production, catalyzed by LDH. In this study, we use ethoxyquin (EQ) as a novel inhibitor to target LDH in murine Ehrlich ascites carcinoma (EAC) and as a combination therapy to improve the therapeutic efficacy of the conventional chemotherapy drug, cisplatin (CIS). We investigated the anti-tumor effect of EQ on EAC-bearing mice and checked whether EQ can sustain the anti-tumor potential of CIS and whether it influences LDH activity. Treatment with EQ had evident anti-tumor effects on EAC as revealed by the remarkable decrease in the expression of the anti-apoptotic gene Bcl-2 and by a significant increase in the expression of apoptotic genes (BAX and caspase-3). EQ also caused a significant decrease in the autophagic activity of EAC cells, as shown by a reduction in the fluorescence intensity of the autophagosome marker. Additionally, EQ restored the altered hematological and biochemical parameters and improved the disrupted hepatic tissues of EAC-bearing mice. Co-administration of EQ and CIS showed the highest anti-tumor effect against EAC. Collectively, our findings propose EQ as a novel inhibitor of LDH in cancer cells and as a combinatory drug to increase the efficacy of cisplatin. Further studies are required to validate this therapeutic strategy in different cancer models and preclinical trials. |
| Keywords | ethoxyquin; LDH; glycolysis; autophagy; cisplatin; Ehrlich ascites carcinoma |
| Year | 2021 |
| Journal | Biomedicines |
| Journal citation | 9 (11), p. e1526 |
| Publisher | MDPI |
| ISSN | 2227-9059 |
| Digital Object Identifier (DOI) | https://doi.org/10.3390/biomedicines9111526 |
| Funder/Client | Academy of Scientific Research and Technology, Scientists of next generation grant. |
| Publication dates | |
| Online | 23 Oct 2021 |
| Publication process dates | |
| Accepted | 22 Oct 2021 |
| Deposited | 10 Nov 2021 |
| Publisher's version | License File Access Level Open |
| License | https://creativecommons.org/licenses/by/4.0/ |
Permalink -
https://openresearch.lsbu.ac.uk/item/8yq83
Download files
94
total views54
total downloads0
views this month3
downloads this month
Export as
Related outputs
Hierarchical Risk Communication Management Framework for Construction Projects
Mansour, M., Beithou, N., Alsqour, M., Tarawneh, S.A., Al Rababa’a, K., AlSaqoor, S. and Chodakowska, E. (2023). Hierarchical Risk Communication Management Framework for Construction Projects. Engineering Management in Production and Services. 15 (4), pp. 104 - 115. https://doi.org/10.2478/emj-2023-0031Spatial regulation of the glycocalyx component podocalyxin is a switch for prometastatic function
Román-Fernández, A., Mansour, M., Kugeratski, F.G., Anand, J., Sandilands, E., Galbraith, L., Rakovic, K., Freckmann, E.C., Cumming, E.M., Park, J., Nikolatou, K., Lilla, S., Shaw, R., Strachan, D., Mason, S., Patel, R., McGarry, L., Katoch, A., Campbell, A.J., Nixon, C., Miller, D.J., Leung, H.Y., Le Quesne, J., Norman, J.C., Zanivan, S., Blyth, K. and Bryant, K.M. (2023). Spatial regulation of the glycocalyx component podocalyxin is a switch for prometastatic function. Science Advances. 9 (5). https://doi.org/10.1126/sciadv.abq1858Synthesis, Anticancer, Antioxidant, Anti-Inflammatory, Antimicrobial Activities, Molecular Docking, and DFT Studies of Sultams Derived from Saccharin
Al-Fayez, N., Elsawy, H., Mansour, M., Akbar Ali, M. and Elghamry, I. (2022). Synthesis, Anticancer, Antioxidant, Anti-Inflammatory, Antimicrobial Activities, Molecular Docking, and DFT Studies of Sultams Derived from Saccharin. Molecules (Basel, Switzerland). 27 (20), p. 7104. https://doi.org/10.3390/molecules27207104Tioconazole and Chloroquine Act Synergistically to Combat Doxorubicin-Induced Toxicity via Inactivation of PI3K/AKT/mTOR Signaling Mediated ROS-Dependent Apoptosis and Autophagic Flux Inhibition in MCF-7 Breast Cancer Cells.
El-Gowily, A.H., Loutfy, S.A., Ali, E., Mohamed, T. and Mansour, M. (2021). Tioconazole and Chloroquine Act Synergistically to Combat Doxorubicin-Induced Toxicity via Inactivation of PI3K/AKT/mTOR Signaling Mediated ROS-Dependent Apoptosis and Autophagic Flux Inhibition in MCF-7 Breast Cancer Cells. Pharmaceuticals. 14 (3). https://doi.org/ph14030254SP3 is associated with migration, invasion, and Akt/PKB signalling in MDA‐MB‐231 breast cancer cells
Mansour, M. (2020). SP3 is associated with migration, invasion, and Akt/PKB signalling in MDA‐MB‐231 breast cancer cells. Journal of biochemical and molecular toxicology. 35 (3). https://doi.org/10.1002/jbt.22657
Dual inhibition of glycolysis and autophagy as a therapeutic strategy in the treatment of Ehrlich ascites carcinoma
Mansour, MA, Ibrahim, WM, Salama, MM and Salama, AF (2020). Dual inhibition of glycolysis and autophagy as a therapeutic strategy in the treatment of Ehrlich ascites carcinoma. Journal of Biochemical and Molecular Toxicology. 34 (7). https://doi.org/10.1002/jbt.22498Assessment of Autophagy as Possible Mechanism of the Antitumor Effects of Arsenic Trioxide and/or Cisplatin on Ehrlich Ascites Carcinoma Model.
Mansour, M.A., Salama, A.F., Ibrahim, W.M. and Shalaan, E.S. (2019). Assessment of Autophagy as Possible Mechanism of the Antitumor Effects of Arsenic Trioxide and/or Cisplatin on Ehrlich Ascites Carcinoma Model. Alexandria Journal for Veterinary Sciences. 61 (1), pp. 159-167. https://doi.org/10.5455/ajvs.29544